Synopsis
Synopsis
0
CEP/COS
0
VMF
0
Canada
0
Australia
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Tazobactam
2. Ytr 830
3. Ytr 830h
4. Ytr-830
5. Ytr830
1. Tazobactam Sodium Salt
2. 89785-84-2
3. Tazobactum Sodium
4. Tazobactam Sodium [usan]
5. Cl-307579
6. Tazobactam (sodium)
7. Ytr-830
8. Tazobactam (as Sodium)
9. Cl 307,579
10. Uxa545abtt
11. Chembl1439
12. Cl 307579
13. Chebi:85192
14. 89785-84-2 (sodium)
15. Ytr 830
16. 2-alpha-methyl-2-beta-(1,2,3-triazol-1-ylmethyl)penam-3-alpha-carboxylic Acid Sodium Salt
17. Dsstox_cid_26030
18. Dsstox_rid_81299
19. Dsstox_gsid_46030
20. 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid, 3-methyl-7-oxo-3-(1h-1,2,3-triazol-1-ylmethyl)-, 4,4-dioxide, Sodium Salt, (2s,3s,5r)-
21. Sodium (2s,3s,5r)-3-methyl-7-oxo-3-(1h-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate, 4,4-dioxide
22. Sodium;(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
23. Cas-89785-84-2
24. Unii-uxa545abtt
25. Tazobactum
26. Ncgc00159340-02
27. Schembl259991
28. Tazobactam Sodium (jan/usan)
29. Tazobactam Sodium [jan]
30. Dtxsid8046030
31. Tazobactam Sodium [vandf]
32. Tazobactam Sodium [mart.]
33. Yp-14
34. Tazobactam Sodium [who-dd]
35. Sodium (2s,3s,5r)-3-((1h-1,2,3-triazol-1-yl)methyl)-3-methyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate 4,4-dioxide
36. Tazobactam Sodium Salt [mi]
37. Tox21_111584
38. Bdbm50157692
39. Mfcd00917472
40. Akos015962921
41. Akos016843926
42. Tox21_111584_1
43. Cs-w009884
44. Hy-w009168
45. Tazobactam Sodium [orange Book]
46. Zosyn Component Tazobactam Sodium
47. Ncgc00159340-05
48. Ac-18978
49. Ac-32478
50. As-56873
51. Zerbaxa Component Tazobactam Sodium
52. Tazobactam Sodium Salt, Analytical Standard
53. Tazobactam Sodium Component Of Zosyn
54. Tazobactam Sodium Component Of Zerbaxa
55. D03707
56. T-1446
57. Tazobactam Sodium Salt, Beta-lactamase Inhibitor
58. Q27158392
59. Tazobactam Sodium Salt, Antibiotic For Culture Media Use Only
60. 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid, 3-methyl-7-oxo-3-(1h-1,2,3-triazol-1-ylmethyl)-, 4,4-dioxide, Sodium Salt, (2s-(2alpha,3beta,5alpha))-
61. Sodium (2s,3s,5r)-3-methyl-4,4,7-trioxo-3-[(1h-1,2,3-triazol-1-yl)methyl]-4lambda(6)-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
62. Sodium (2s,3s,5r)-3-methyl-4,4,7-trioxo-3-[1,2,3]triazol-1-ylmethyl-4lambda6-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylate
63. Sodium(2s,3s,5r)-3-((1h-1,2,3-triazol-1-yl)methyl)-3-methyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate4,4-dioxide
64. Sodium; (2s,3s,5r)-3-methyl-4,4,7-trioxo-3-[1,2,3]triazol-1-ylmethyl-4lambda*6*-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylate
| Molecular Weight | 322.28 g/mol |
|---|---|
| Molecular Formula | C10H11N4NaO5S |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 3 |
| Exact Mass | 322.03478492 g/mol |
| Monoisotopic Mass | 322.03478492 g/mol |
| Topological Polar Surface Area | 134 Ų |
| Heavy Atom Count | 21 |
| Formal Charge | 0 |
| Complexity | 579 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
beta-Lactamase Inhibitors
Endogenous substances and drugs that inhibit or block the activity of BETA-LACTAMASES. (See all compounds classified as beta-Lactamase Inhibitors.)
API SUPPLIERS
HRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38374
Submission : 2023-09-12
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-01-31
Pay. Date : 2013-01-08
DMF Number : 20428
Submission : 2007-04-05
Status : Active
Type : II
Registration Number : 229MF10179
Registrant's Address : No. 10678 Wenliang Road, Dongjia Town, Licheng District, Jinan, Shandong Province, P. R. CHINA
Initial Date of Registration : 2017-09-21
Latest Date of Registration : --
Registrant Name : Korea MSD Co., Ltd.
Registration Date : 2020-08-10
Registration Number : 20200810-210-J-449
Manufacturer Name : Shandong Anxin Pharmaceutical Co., Ltd. (formerly Qilu Tianhe Pharmaceutical. Co. Ltd)
Manufacturer Address : No. 849, Dongjia Town, Licheng District, 250105 Jinan, Shandong Province, PR of China
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-07-26
Pay. Date : 2013-11-22
DMF Number : 27140
Submission : 2013-04-25
Status : Active
Type : II
Registrant Name : Korea MSD Co., Ltd.
Registration Date : 2020-08-10
Registration Number : 20200810-210-J-449
Manufacturer Name : Shandong Anxin Pharmaceutical Co., Ltd. (formerly Qilu Tianhe Pharmaceutical. Co. Ltd)
Manufacturer Address : No. 849, Dongjia Town, Licheng District, 250105 Jinan, Shandong Province, PR of China
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-09-04
Pay. Date : 2019-07-31
DMF Number : 33978
Submission : 2019-07-30
Status : Active
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-03-20
Pay. Date : 2017-08-28
DMF Number : 31398
Submission : 2017-08-30
Status : Active
Type : II
Registration Number : 217MF10481
Registrant's Address : Osaka City, Osaka Prefecture, Chuo Ward, Ote-dori 3-2-27
Initial Date of Registration : 2005-09-06
Latest Date of Registration : --
NDC Package Code : 60212-352
Start Marketing Date : 1993-02-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-03-06
Pay. Date : 2022-04-14
DMF Number : 36268
Submission : 2022-05-23
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18710
Submission : 2005-08-25
Status : Inactive
Type : II
NDC Package Code : 58623-0062
Start Marketing Date : 2013-12-16
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24963
Submission : 2011-05-18
Status : Inactive
Type : II
NDC Package Code : 58623-0062
Start Marketing Date : 2013-12-16
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23674
Submission : 2010-03-31
Status : Inactive
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
GDUFA
DMF Review : Complete
Rev. Date : 2021-12-16
Pay. Date : 2021-12-13
DMF Number : 19823
Submission : 2006-09-27
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 29675
Submission : 2015-08-31
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18506
Submission : 2005-07-11
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23674
Submission : 2010-03-31
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-03-20
Pay. Date : 2017-08-28
DMF Number : 31398
Submission : 2017-08-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24662
Submission : 2011-01-29
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-01-31
Pay. Date : 2013-01-08
DMF Number : 20428
Submission : 2007-04-05
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-07-26
Pay. Date : 2013-11-22
DMF Number : 27140
Submission : 2013-04-25
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25968
Submission : 2012-03-15
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24963
Submission : 2011-05-18
Status : Inactive
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
Date of Issue : 2019-07-05
Valid Till : 2022-07-02
Written Confirmation Number : WC-0121
Address of the Firm : Unit-V, Plot No.79-91, IDA, Chemical Zone, Pashamylaram (V), Patancheru (M), Med...
Date of Issue : 2018-11-02
Valid Till : 2022-11-03
Written Confirmation Number : WC-0430
Address of the Firm : Plot No L9 MIDC Waluj Aurangabad 431136
Date of Issue : 2018-12-05
Valid Till : 2021-04-01
Written Confirmation Number : WC-0420
Address of the Firm : Unit-II A-619 & 630 RIICO Industrial Area Bhiwadi-301019 Distt. Alwar Rajasthan
Date of Issue : 2020-04-16
Valid Till : 2022-07-06
Written Confirmation Number : WC-0378A2
Address of the Firm : Plot No 100 Sector 56, HSIIDC, Kundli district sonepat, Haryana
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - INJECTABLE;INJECTION - EQ 2GM BASE/V...DOSAGE - INJECTABLE;INJECTION - EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50684
DOSAGE - INJECTABLE;INJECTION - EQ 36GM BASE/...DOSAGE - INJECTABLE;INJECTION - EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50684
DOSAGE - INJECTABLE;INJECTION - EQ 3GM BASE/V...DOSAGE - INJECTABLE;INJECTION - EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50684
DOSAGE - INJECTABLE;INJECTION - EQ 4GM BASE/V...DOSAGE - INJECTABLE;INJECTION - EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50684
DOSAGE - INJECTABLE;INJECTION - EQ 40MG BASE/...DOSAGE - INJECTABLE;INJECTION - EQ 40MG BASE/ML;EQ 5MG BASE/ML
USFDA APPLICATION NUMBER - 50750
DOSAGE - INJECTABLE;INJECTION - EQ 4GM BASE/1...DOSAGE - INJECTABLE;INJECTION - EQ 4GM BASE/100ML;EQ 500MG BASE/100ML
USFDA APPLICATION NUMBER - 50750
DOSAGE - INJECTABLE;INJECTION - EQ 60MG BASE/...DOSAGE - INJECTABLE;INJECTION - EQ 60MG BASE/ML;EQ 7.5MG BASE/ML
USFDA APPLICATION NUMBER - 50750
Related Excipient Companies
SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Parenteral
Fillers, Diluents & Binders
Thickeners and Stabilizers
API Stability Enhancers
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Tazobactam Sodium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tazobactam Sodium, including repackagers and relabelers. The FDA regulates Tazobactam Sodium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tazobactam Sodium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Tazobactam Sodium manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Tazobactam Sodium supplier is an individual or a company that provides Tazobactam Sodium active pharmaceutical ingredient (API) or Tazobactam Sodium finished formulations upon request. The Tazobactam Sodium suppliers may include Tazobactam Sodium API manufacturers, exporters, distributors and traders.
click here to find a list of Tazobactam Sodium suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Tazobactam Sodium DMF (Drug Master File) is a document detailing the whole manufacturing process of Tazobactam Sodium active pharmaceutical ingredient (API) in detail. Different forms of Tazobactam Sodium DMFs exist exist since differing nations have different regulations, such as Tazobactam Sodium USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Tazobactam Sodium DMF submitted to regulatory agencies in the US is known as a USDMF. Tazobactam Sodium USDMF includes data on Tazobactam Sodium's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Tazobactam Sodium USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Tazobactam Sodium suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Tazobactam Sodium Drug Master File in Japan (Tazobactam Sodium JDMF) empowers Tazobactam Sodium API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Tazobactam Sodium JDMF during the approval evaluation for pharmaceutical products. At the time of Tazobactam Sodium JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Tazobactam Sodium suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Tazobactam Sodium Drug Master File in Korea (Tazobactam Sodium KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Tazobactam Sodium. The MFDS reviews the Tazobactam Sodium KDMF as part of the drug registration process and uses the information provided in the Tazobactam Sodium KDMF to evaluate the safety and efficacy of the drug.
After submitting a Tazobactam Sodium KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Tazobactam Sodium API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Tazobactam Sodium suppliers with KDMF on PharmaCompass.
A Tazobactam Sodium written confirmation (Tazobactam Sodium WC) is an official document issued by a regulatory agency to a Tazobactam Sodium manufacturer, verifying that the manufacturing facility of a Tazobactam Sodium active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Tazobactam Sodium APIs or Tazobactam Sodium finished pharmaceutical products to another nation, regulatory agencies frequently require a Tazobactam Sodium WC (written confirmation) as part of the regulatory process.
click here to find a list of Tazobactam Sodium suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tazobactam Sodium as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Tazobactam Sodium API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Tazobactam Sodium as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Tazobactam Sodium and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tazobactam Sodium NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Tazobactam Sodium suppliers with NDC on PharmaCompass.
Tazobactam Sodium Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tazobactam Sodium GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tazobactam Sodium GMP manufacturer or Tazobactam Sodium GMP API supplier for your needs.
A Tazobactam Sodium CoA (Certificate of Analysis) is a formal document that attests to Tazobactam Sodium's compliance with Tazobactam Sodium specifications and serves as a tool for batch-level quality control.
Tazobactam Sodium CoA mostly includes findings from lab analyses of a specific batch. For each Tazobactam Sodium CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tazobactam Sodium may be tested according to a variety of international standards, such as European Pharmacopoeia (Tazobactam Sodium EP), Tazobactam Sodium JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tazobactam Sodium USP).
LOOKING FOR A SUPPLIER?
